CORE E: NOVEL TARGET DISCOVERY AND ASSAY

核心 E：新靶标发现和测定

• 批准号: 8443941
• 负责人: Julian P Whitelegge
• 金额: $ 20.43万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-05-01 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8443941
• 关键词: Address; Animal Experiments; Binding; Bioinformatics; Biological; Biological Assay; Biological Markers; Biological Process; Biology; Cells; Clinic; Clinical; Communication; Communities; Complement; Complications of Diabetes Mellitus; Computer software; Consult; Continuing Education; Data; Databases; Development; Diabetes Mellitus; Enzyme-Linked Immunosorbent Assay; Epigenetic Process; Foundations; Funding; Genetic; Genomics; Goals; Homologous Gene; Human; Human Genetics; Individual; Inflammatory; Institutes; Insulin; Insulin Resistance; Insulin-Like Growth-Factor-Binding Proteins; Ions; Knockout Mice; Label; Lead; Leadership; Learning; Length; Liquid Chromatography; Mass Spectrum Analysis; Measurement; Measures; Metabolic; Metabolism; Mission; Molecular; Monitor; Mus; Obesity; Outcome; Patients; Peptides; Performance; Physiology; Post-Translational Protein Processing; Prevention; Protein Analysis; Protein Isoforms; Proteins; Proteomics; Qualifying; Quality Control; Reaction; Reagent; Relative (related person); Research; Research Personnel; Resolution; Resources; Sampling; Services; Signal Transduction; Stable Isotope Labeling; Statistical Data Interpretation; Strategic Planning; Structure; System; Testing; Transgenic Organisms; Translating; Translations; Validation; assay development; biological systems; clinical assay development; clinically relevant; combat; cost effective; data mining; design; empowered; experience; high throughput screening; humanin; improved; interest; mass spectrometer; meetings; member; nano; novel; novel therapeutics; outreach; polyclonal antibody; research study; scaffold; statistics; synthetic peptide; tandem mass spectrometry

The Novel Target Discovery and Assay Development Core (NTDAC) will provide investigators at UCLA, UCSD, the Salk Institute and Cedars-Sinai with consultancy and a suite of state-of-the-art molecular measurements not available from other national resources. The new NTDAC core assembles a comprehensive and highly specialized core with expertize in biological mass spectrometry and proteomics (Julian Whitelegge, Director) and ELISA assay development (Pinchas Cohen, Co-Director). Strengths of this biomedical core include the extensive expertise ofthe core leadership in diabetes research, wide experience in protein and peptide analysis, access to bioinformatics resources, and the collegial outreach of NTDAC leadership to DRC investigators to assist in the strategic planning and execution of studies relevant to the DRC mission. Core goals include: 1) provide an accessible user interface toward meeting objectives in a timely, cost effective, and integrated manner individualized to the specific needs of each DRC investigator, 2) provide discovery mass spectrometry services with appropriate bioinformafics for sensitive, accurate measurements with quality control, 3) provide biomarker qualificafion, immunocapture and top-down mass spectrometry for qualification of lead proteins and peptides with respect to biological function, 4) provide assay construction for novel peptides and proteins, and optimization of reliable assays toward the clinic, 5) provide ELISA services for novel assays for development of new clinical assays for better pafient outcomes in diabetes. The collective and complementary expertise of the core leadership is outstanding and provides DRC invesfigators with an opportunity to explore and implement experimental strategies that rely upon direct analysis of proteins and peptides. The new NTDAC core provides discovery proteomics and peptidomics, alongside the lipidomics component that has been introduced into the MMPC (core B). The core will synergize with the other DRC cores through many favorable interactions including identification of interaction partners (core A), integrafion with metabolism and physiology studies (core B) and enhanced bioinformatics resources related to the genomics and genetics cores (C & D). Collectively, our ability to study the proteins and peptides of insulin action, substrate metabolism, and inflammatory signaling will drive the UCSD-UCLA DRC fonfl/ard in discovery of critical biological molecules involved in the pathobiology of obesity and insulin resistance, and provide a foundation for the development of novel therapeutic strategies to combat diabetes and diabetes complications.

新靶点发现和分析开发核心（NTDAC）将为加州大学洛杉矶分校的研究人员，